December 28, 2010
by Matt Glenn
The Securities and Exchange Commission (SEC) has filed an insider trading complaint against unknown investors in Martek Biosciences Corp., claiming that the investors purchased an unusually large number of call options in Martek in the two weeks preceding the December 21 announcement that DSM ...[read more]

Support JURIST

We rely on our readers to keep JURIST running

 Donate now!

© Copyright JURIST Legal News and Research Services, Inc., 2013.